Loading…
← CockpitCompetitor Analysis › 002737.SZ Sunflower Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Sunflower Pharmaceutical Group Co., Ltd. Class A002737.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 81
Mkt cap
$1.04B
US dollars, full cap
Free float
36%
of shares outstanding
$/day
$10.3M
20-day average traded
Fwd P/E
4.7×
forward earnings
ROIC−WACC
-8.1 pp
WACC 5.0%
Hurdle
+1 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥12.01
1D+1.4%
1W+1.6%
1M+6.8%
3M-11.9%
6M-11.0%
YTD-18.7%
1Y-17.2%
ATR %2.2%
52w lowhigh22.1% off high

What Sunflower Pharmaceutical does

Employees: 5,025

Sunflower Pharmaceutical at a glance

Size Sunflower Pharmaceutical (002737.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.04B, the 2097th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.01 on 18 Nov 2026.

Performance Over six months the shares fell 11.0%, against -11.0% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 31.4% over the last twelve months (peer median +3.9%); the operating margin is -7.2% (peer median 8.6%).

Valuation It trades at 4.7× forward earnings against a peer median of 16.9× (2nd cheapest of 14).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.1 points below its cost of capital (5.0% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 92002737.SZ 91
Six months, rebased to 100: Sunflower Pharmaceutical against the median of its 20 peers (local-currency closes).

Sunflower Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.75BCN¥2.30BCN¥3.35BCN¥5.66BCN¥5.05B
Revenue growth—-31%-41%+12%—
Gross profitCN¥1.49BCN¥807MCN¥1.44BCN¥3.10BCN¥2.84B
EBITDAn/a-CN¥118MCN¥639MCN¥1.36BCN¥1.29B
Net income-CN¥141M-CN¥258MCN¥492MCN¥1.12BCN¥867M
Free cash flowCN¥359MCN¥514M-CN¥366MCN¥774MCN¥1.84B
Capital expenditureCN¥106MCN¥96.1MCN¥92.8MCN¥149MCN¥153M
Total debtCN¥299MCN¥151MCN¥10.2MCN¥30.1MCN¥436M

Quarterly statements and history in the cockpit →

Sunflower Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%4553SVRABSLN688513600789300497BLUEJET19523007020006504887688091605116688710OMER600812AARTIPHARMMEDCL688382002737.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Sunflower Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×4553BSLN688513300497BLUEJET1952300702000650605116688710002737.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sunflower Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-50%-25%0%+25%-50%0%4553BSLN688513300497BLUEJET000650605116688710600812600557688382002737.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sunflower Pharmaceutical is the large dot.

Sunflower Pharmaceutical competitors and peer comparison

How Sunflower Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sunflower Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002737.SZPeer medianRank in peer set
1-month return+6.8%-8.3%2nd highest of 21
6-month return-11.0%-11.0%11th highest of 21
Distance from 52-week high-22.1%-32.1%5th highest of 21
Revenue growth (TTM)+31.4%+3.9%4th highest of 19
Operating margin-7.2%8.6%4th lowest of 20
Forward P/E4.7×16.9×2nd cheapest of 14
Growth the price implies (Req g, 7 yrs)-6.5%2.5%2nd least demanding of 14
Growth delivered (Del g)-7.7%+6.5%2nd lowest of 14
Hurdle (Req g minus delivered)+1.1 pp-3.3 pp5th most demanding of 14
ROIC minus cost of capital-8.1 pp+0.4 pp3rd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%

Questions

Which companies are Sunflower Pharmaceutical's closest peers?
The cockpit's peer set: Towa Pharmaceutical (4553.T), Savara (SVRA), Basilea Pharmaceutica (BSLN.SW), Chengdu Easton Biopharmaceuticals (688513.SS), Shandong Lukang Pharmaceutical (600789.SS), Jiangxi Fushine Pharmaceutical (300497.SZ), Blue Jet Healthcare (BLUEJET.NS), Everest Medicines (1952.HK).
Is Sunflower Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 4.7× against a peer median of 16.9×, 2nd cheapest of 14 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -8%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sunflower Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -11.0% against -11.0% for the median peer; over one year -17.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.